Shots:
Abdul spoke about the launch of a digital exhibition ‘Shine a light’ to raise awareness about rare diseases
Abdul also emphasized the significance of this awareness campaign for the patients who were unaware of X-linked Hypophosphataemia(XLH)
The interview provides a profound understanding of Kyowa Kirin's initiatives to help patients suffering from XLH
Smriti: Can we…
Shots:
Daphne talked about the P-III study evaluating the safety and efficacy of Tremfya in people of color living with moderate to severe plaque psoriasis
Daphne also spoke about how this clinical study will contribute to fill the gaps in care of people who are devoid of treatment due to racial and ethnic variations
The…
Shots:
Shmulik spoke about the key features and development of the new AI tool for Prostate MRI Analysis
Shmulik emphasized the significance of this new tool in PI-RADS score and how this can be helpful in diagnosing prostate lesions in MRI
The interview provides a deeper understanding of medical imaging technologies that are emerging through…
PharmaShots Team is pleased to announce the completion of our 4 years, PharmaShots commenced its journey on the path of delivering real-time concise news focused on the Global Healthcare and Life Sciences Industry
With a flourishing completion of 4 years, PharmaShots is delighted to announce an upgraded App, Exclusive & Spotlight Interviews, and ThoughtSpot services, along with a launch…
The US FDA approved 2 NDAs and 2 BLA in June 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 37 novel products in 2022
In June 2022, the major highlights drugs were Amvuttra's approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Skyrizi for active Crohn's disease, Olumiant…
Shots:
Kathy spoke about the major outcomes from the real-world evidence data presented at the ASCO 2022
Kathy also emphasized on how next-generation sequencing can improve genomic testing
The interview gives a view of Thermo Fisher’s vision to bring targeted sequencing that provides faster results for clinicians
Smriti: Tell us in detail about the key…
Shots:
Mahesh talked about the data presented on its lead candidate in hepatocellular carcinoma at the AACR 2022
Mahesh also spoke about Omega’s drug-development platform that identifies and targets specific and unique DNA sequences of regulatory elements
The interview gives a profound grip on Omega’s development strategies to use mRNA therapeutics as a new class…
Shots:
Barbara gave a comprehensive view of the P-III (MOMENTUM) clinical study results which evaluates its lead candidate in myelofibrosis
Sierra is now acquired by GSK (completed on 1st July 2022) resulting in GSK commercializing this prime product once approved
The interview outlines Sierra’s (now GSK) vision to develop transformative therapies for rare cancers
Smriti: Thank…
Shots:
Bassem spoke about the new data presented in a poster presentation at the ACOG annual meeting
The data was based on the P-III (AMPOWER) study, which evaluates Evofem’s nonhormonal contraceptive gel to prevent pregnancy
The interview gives an understanding of how Evofem is developing innovative products to improve women's healthÂ
Smriti: Please highlight the study…
Shots:
Kyle Forcier gave a detailed view of the Spring 2022 product release by Model N and how it will be a practical solution for the Pharmaceutical and MedTech companies
Kyle also spoke about Model N’s Revenue Cloud, which can empower MedTech Sales with better revenue recognition
The interview gives a glimpse of Model N’s…

